Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04834674

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Drug-eluting Beads Transarterial Chemoembolization Combined With Apatinib and PD-1 Antibody for the Treatment of Intrahepatic Cholangiocarcinoma That Has Progressed After Standard First-line Chemotherapy

Sponsor: Sichuan Cancer Hospital and Research Institute

Conditions Apatinib Intrahepatic Cholangiocarcinoma PD-1 Antibody Transarterial Chemoembolization

Interventions DEB-TACE combined with apatinib and PD-1 antibody

Updated 4 times since 2021 Last updated: Jun 22, 2024 Started: Jul 1, 2024 Primary completion: Apr 30, 2025 Completion: Apr 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Apatinib and Intrahepatic Cholangiocarcinoma and is currently actively recruiting participants. Sichuan Cancer Hospital and Research Institute leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting
Jun 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
May 2021 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Cancer Hospital and Research Institute

Data source: Sichuan Cancer Hospital and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China